GLP-1 and Testosterone: What Men Need to Know in 2026

If you're a man considering a GLP-1 medication for weight loss, you've probably heard the concerns: will it tank your testosterone? Will you feel worse, even as you lose weight? The latest clinical evidence says the opposite is far more likely.

Research presented at ENDO 2025 — the Endocrine Society's flagship annual meeting — shows that GLP-1 medications don't just help men lose weight. They appear to restore testosterone levels that obesity had suppressed, without requiring testosterone replacement therapy.

The ENDO 2025 Study: 110 Men, 18 Months, No TRT

Dr. Shellsea Portillo Canales and colleagues at SSM Health St. Louis University Hospital conducted a retrospective analysis of 110 adult men with obesity or type 2 diabetes who were treated with semaglutide, dulaglutide, or tirzepatide for 18 months. Critically, none of these men were receiving testosterone replacement or any other hormonal therapy.

That's a 24-percentage-point increase in testosterone normalization achieved purely through metabolic improvement. The men lost approximately 10% of their body weight, and their hormonal profiles followed.

Dr. Portillo Canales stated in her presentation: this study represents some of the first compelling evidence that low testosterone can be reversed with commonly prescribed anti-obesity medications.

Why Obesity Kills Testosterone

The mechanism is well-established in endocrinology. Visceral fat tissue — the deep abdominal fat that wraps around organs — contains high concentrations of the aromatase enzyme. Aromatase converts testosterone into estradiol (a form of estrogen). The more visceral fat a man carries, the more testosterone he loses to this conversion process.

This creates a vicious cycle: low testosterone promotes further fat storage (particularly abdominal), which increases aromatase activity, which further lowers testosterone. Clinically, this is called obesity-related functional hypogonadism, and it affects an estimated 30–50% of men with BMI above 30.

GLP-1 medications break this cycle by reducing visceral fat directly. As fat mass drops, aromatase activity decreases, and the body retains more of its own testosterone production.

Tirzepatide vs. TRT: Head-to-Head Data

A separate study presented at ENDO 2025 went further, directly comparing tirzepatide to testosterone replacement therapy in 83 men with functional hypogonadism. The results challenge the assumption that TRT is always the right answer for low-T men with obesity.

The lead researcher, Dr. Rossella Cannarella, described tirzepatide as potentially "a safer and more sustainable option" than TRT for men whose low testosterone is driven by obesity.

The Fertility Factor: Why This Matters for Younger Men

One of the most significant clinical distinctions between GLP-1 therapy and TRT is the effect on sperm production. TRT suppresses the hypothalamic-pituitary-gonadal axis — essentially telling the brain that testosterone levels are sufficient, which shuts down natural production and drastically reduces sperm output.

A systematic review published in Andrology (March 2025) found that TRT caused a 60.6% decrease in sperm concentration, while GLP-1 therapy was associated with improved sperm morphology. An AUA 2025 retrospective analysis of approximately 4,000 men found significant improvements in sperm count among GLP-1 users compared to controls (p=0.001).

For men in their 30s and 40s who want to address both weight and low testosterone without compromising their ability to have children, this distinction is not minor — it's decisive.

Broader Hormonal Benefits

The hormonal improvements extend beyond just total testosterone. A systematic review across multiple GLP-1 trials confirmed statistically significant increases in:

• Total testosterone — the headline number on blood work
• Free testosterone — the bioavailable fraction that actually drives symptoms
• Gonadotropins (LH and FSH) — indicating restored pituitary signaling rather than artificial replacement

The gonadotropin finding is particularly important. Rising LH and FSH levels mean the brain's hormonal control system is re-engaging — a sign of genuine metabolic recovery, not a pharmaceutical workaround.

What This Means for You

If you're a man with a BMI above 30 and your blood work shows low testosterone, there's now strong clinical evidence suggesting that GLP-1 therapy may address both issues simultaneously. The data doesn't mean every man will normalize his testosterone on these medications — individual factors including age, baseline levels, and the degree of obesity all play a role.

But the ENDO 2025 data reframes the conversation. GLP-1 medications aren't just weight loss tools. For many men, they appear to function as indirect hormone optimization — restoring what obesity disrupted, through the body's own pathways.

Questions to bring to your doctor

• What are my current total and free testosterone levels?
• Is my low-T likely obesity-related (functional hypogonadism)?
• Would a GLP-1 medication be appropriate before starting TRT?
• Should we recheck testosterone after 6 months of treatment?
• Am I planning for children in the next few years? (if yes, GLP-1 strongly preferred over TRT)